PTC Therapeutics (NASDAQ:PTCT) Posts Earnings Results

PTC Therapeutics (NASDAQ:PTCT) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.76), FiscalAI reports. The firm had revenue of $357.81 million for the quarter, compared to analysts’ expectations of $306.43 million. The business’s revenue for the quarter was up 69.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.20 EPS.

Here are the key takeaways from PTC Therapeutics’ conference call:

• Guidance was raised after a record quarter: Third-quarter total revenue reached $358 million, including $276 million in product revenue, and 2026 product revenue guidance increased to $960 million–$990 million. Management also reiterated its expectation to reach cash-flow breakeven this year.
• SEPHIENCE launch momentum remains strong: Global SEPHIENCE revenue was $182 million, up more than 20% sequentially, with over 2,000 active patients worldwide and strong adherence. PTC said the U.S. launch is entering a durable growth phase and maintained its confidence in a $2 billion-plus peak-sales opportunity.
• ST-920 adds a potentially near-term growth driver: PTC expects to complete its rolling BLA submission for the Fabry gene therapy in the fourth quarter, with potential approval and launch in 2027. The company said the $111 million acquisition could be accretive in 2027 and noted ST-920’s RMAT designation may support priority review.
• Mature DMD products face increasing pressure: A new Emflaza generic entrant has significantly reduced pricing, while Translarna’s third-quarter revenue benefited from an unexpected Russian government order that PTC does not expect to repeat in the fourth quarter.
• Votoplam’s regulatory discussion was delayed: The FDA Type C meeting on the Huntington’s disease program is now expected in the first quarter of 2027 rather than late 2026, although global enrollment in the 770-patient INVEST-HD Phase III study continues.

PTC Therapeutics Price Performance

Shares of PTCT stock traded down $2.60 during trading hours on Friday, hitting $61.86. The stock had a trading volume of 675,874 shares, compared to its average volume of 1,343,994. PTC Therapeutics has a one year low of $58.80 and a one year high of $90.87. The stock’s 50-day moving average price is $65.57 and its two-hundred day moving average price is $70.87. The stock has a market capitalization of $5.16 billion, a price-to-earnings ratio of -106.48, a PEG ratio of 1.90 and a beta of 0.49.

PTC Therapeutics News Summary

Here are the key news stories impacting PTC Therapeutics this week:

• Positive Sentiment: Third-quarter revenue rose 69.6% year over year to approximately $358 million, exceeding the roughly $306 million analyst consensus. Product revenue totaled $276 million, led by $182 million from Sephience (sepiapterin), which continued to expand in the United States and internationally. PTC Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
• Positive Sentiment: PTC raised its 2026 outlook, now forecasting total revenue of $1.29 billion to $1.32 billion and product revenue of $960 million to $990 million. The higher outlook reinforces expectations for continued commercial momentum from Sephience and PTC’s broader product portfolio. PTC Therapeutics Raises 2026 Outlook as Q3 Revenue Hits $358 Million
• Positive Sentiment: The company acquired ST-920, a Fabry disease gene therapy, and expects to complete its biologics license application submission in the fourth quarter. The transaction adds another potential growth driver, although it also brings development and regulatory execution risk. PTC Therapeutics Corporate Update
• Neutral Sentiment: Adjusted earnings were reported by one source at $0.61 per share, above the $0.17 consensus estimate, while other reports focused on a GAAP loss of $0.62 per share versus expectations for a $0.14 profit. The differing measures may create mixed investor interpretations of the quarter’s profitability.
• Negative Sentiment: The reported GAAP loss and year-over-year reversal from $0.20 of earnings highlight continued earnings volatility despite strong sales. This profitability miss appears to be offsetting some of the positive impact from the revenue beat and increased guidance. PTC Therapeutics Swings to Q3 Loss, Revenue Rises; Increases 2026 Outlook

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on PTCT. Royal Bank Of Canada lowered their target price on shares of PTC Therapeutics from $85.00 to $75.00 and set a “sector perform” rating on the stock in a report on Wednesday, October 7th. Wells Fargo & Company upped their target price on shares of PTC Therapeutics from $106.00 to $109.00 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Wall Street Zen lowered shares of PTC Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 10th. Leerink Partners started coverage on PTC Therapeutics in a research note on Monday, September 14th. They issued an “outperform” rating and a $98.00 target price for the company. Finally, Raymond James Financial set a $106.00 price target on PTC Therapeutics in a research report on Tuesday, October 20th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, PTC Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $94.93.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, Director Glenn Steele, Jr. sold 12,000 shares of the company’s stock in a transaction on Wednesday, September 30th. The stock was sold at an average price of $65.16, for a total value of $781,920.00. Following the transaction, the director owned 22,500 shares of the company’s stock, valued at $1,466,100. This represents a 34.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Mark Boulding sold 435 shares of the stock in a transaction that occurred on Tuesday, October 6th. The shares were sold at an average price of $64.16, for a total transaction of $27,909.60. Following the transaction, the vice president owned 105,272 shares in the company, valued at approximately $6,754,251.52. This represents a 0.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 77,370 shares of company stock worth $5,322,261. 5.30% of the stock is currently owned by insiders.

About PTC Therapeutics

PTC Therapeutics, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Its research programs include small-molecule treatments, gene therapies and other approaches designed to address conditions with limited or no available treatment options.

The company’s commercial portfolio has included Emflaza (deflazacort), a corticosteroid approved in the United States to treat Duchenne muscular dystrophy, and Upstaza (eladocagene exuparvovec), a gene therapy authorized in the European Union for aromatic L-amino acid decarboxylase deficiency.